Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in  the  stools,  diarrhea  or  constipation,  weight  loss  due  to  unknown  reason  and  abdominal  pain.  Treatment  includes surgery and medications (NSAIDs).

The Familial Adenomatous Polyposis – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects.

Key Targets in the Familial Adenomatous Polyposis Pipeline Drugs Market

The key targets in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase, Casein Kinase I Isoform Alpha, Collagen Alpha 1(VII) Chain, Interleukin 10 Receptor, and Janus Kinase among others.

Familial Adenomatous Polyposis Drugs Market, by Targets

Familial Adenomatous Polyposis Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Familial Adenomatous Polyposis Pipeline Drugs Market

The key mechanisms of action in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase Inhibitor, Casein Kinase I Isoform Alpha Activator, Collagen Alpha 1(VII) Chain Activator, Janus Kinase Inhibitor, and Interleukin 10 Receptor Agonist.

Familial Adenomatous Polyposis Pipeline Drugs Market, by MoA

Familial Adenomatous Polyposis Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Familial Adenomatous Polyposis Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Familial Adenomatous Polyposis pipeline drugs market are Subcutaneous, Intravenous, Oral, and Intradermal.

Familial Adenomatous Polyposis Pipeline Drugs Market Analysis, by RoA

Familial Adenomatous Polyposis Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Familial Adenomatous Polyposis Pipeline Drugs Market

The key molecule types in the Familial Adenomatous Polyposis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Gene Therapy, Synthetic Peptide, Protein and Subunit Vaccine among others.

Familial Adenomatous Polyposis Pipeline Drugs Market, by Molecule Type

Familial Adenomatous Polyposis Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Familial Adenomatous Polyposis Pipeline Drugs Market

The major companies in the Familial Adenomatous Polyposis pipeline drugs market are Cancer Prevention Pharmaceuticals Inc, ADT Pharmaceuticals Inc, Cellix Bio Pvt Ltd, DNAlite  Therapeutics  Inc, and Eloxx Pharmaceuticals Inc among others.

Familial Adenomatous Polyposis Pipeline Drugs Market, by Major Companies

Familial Adenomatous Polyposis Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Familial Adenomatous Polyposis Pipeline Drugs Market Overview

Key Targets Ornithine Decarboxylase, Casein Kinase I Isoform Alpha, Collagen Alpha 1(VII) Chain, Interleukin 10 Receptor, and Janus Kinase among others.
Key Mechanisms of action Ornithine Decarboxylase Inhibitor, Casein Kinase I Isoform Alpha Activator, Collagen Alpha 1(VII) Chain Activator, Janus Kinase Inhibitor, and Interleukin 10 Receptor Agonist

 

Key Routes of Administration Subcutaneous, Intravenous, Oral, and Intradermal
Key molecule types Monoclonal Antibody, Small Molecule, Recombinant Protein, Gene Therapy, Synthetic Peptide, Protein and Subunit Vaccine
Major companies Cancer Prevention Pharmaceuticals Inc, ADT Pharmaceuticals Inc, Cellix  Bio  Pvt  Ltd, DNAlite  Therapeutics  Inc, and Eloxx Pharmaceuticals Inc among others.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Familial Adenomatous Polyposis

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

ADT Pharmaceuticals Inc
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Eloxx Pharmaceuticals Inc
Emtora Biosciences
FunPep Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KD Pharma Group SA
Recursion Pharmaceuticals Inc
SanaRx Biotherapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
TherapyX Inc
Thetis Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Familial Adenomatous Polyposis – Overview

Familial Adenomatous Polyposis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Familial Adenomatous Polyposis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Familial Adenomatous Polyposis – Companies Involved in Therapeutics Development

ADT Pharmaceuticals Inc

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

DNAlite Therapeutics Inc

Eloxx Pharmaceuticals Inc

Emtora Biosciences

FunPep Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

KD Pharma Group SA

Recursion Pharmaceuticals Inc

SanaRx Biotherapeutics Inc

Stemsynergy Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

TherapyX Inc

Thetis Pharmaceuticals LLC

Familial Adenomatous Polyposis – Drug Profiles

(eflornithine hydrochloride + sulindac) – Drug Profile

Product Description

Mechanism Of Action

History of Events

CLXONC-575 – Drug Profile

Product Description

Mechanism Of Action

FAPXIL SR – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Familial Adenomatous Polyposis – Drug Profile

Product Description

Mechanism Of Action

guselkumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

icosapent ethyl – Drug Profile

Product Description

Mechanism Of Action

History of Events

interleukin-10 SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

lorpucitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

magnesium lysinate bis eicosapentaenoate – Drug Profile

Product Description

Mechanism Of Action

History of Events

ombipepimut-s – Drug Profile

Product Description

Mechanism Of Action

History of Events

pyrvinium pamoate – Drug Profile

Product Description

Mechanism Of Action

History of Events

REC-4881 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SB-201 – Drug Profile

Product Description

Mechanism Of Action

SHR-1020 – Drug Profile

Product Description

Mechanism Of Action

sirolimus – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Familial Adenomatous Polyposis – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit PDE10 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic peptide for Familial Adenomatous Polyposis – Drug Profile

Product Description

Mechanism Of Action

History of Events

ZKN-013 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Familial Adenomatous Polyposis – Dormant Projects

Familial Adenomatous Polyposis – Discontinued Products

Familial Adenomatous Polyposis – Product Development Milestones

Featured News & Press Releases

Oct 12, 2021: Flynpovi: Withdrawal of the marketing authorisation application

Sep 29, 2021: Recursion is granted orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis

Jul 23, 2021: Cancer Prevention Pharmaceuticals has requested a re-examination of EMA’s June 2021 opinion on Flynpovi

Jun 25, 2021: CHMP adopted a negative opinion on the marketing authorisation application for Flynpovi

Sep 11, 2020: Cancer Prevention Pharmaceuticals Announces NEJM publication of landmark phase 3 clinical trial for treatment of familial adenomatous polyposis

Jun 29, 2020: Cancer Prevention Pharmaceuticals submits New Drug Application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis

Jun 18, 2020: Cancer Prevention Pharmaceuticals submits EU marketing authorization application for CPP-1X/sul for treatment of familial adenomatous polyposis

Apr 15, 2020: KD Pharma and SLA Pharma to study EPAspire for Covid-19

Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx

Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis

Aug 01, 2019: SLA Pharma announces meeting with the FDA in October 2019 for ALFA

Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference

May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis

Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis

Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Familial Adenomatous Polyposis, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Familial Adenomatous Polyposis – Pipeline by ADT Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Cancer Prevention Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Cellix Bio Pvt Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by DNAlite Therapeutics Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Eloxx Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Emtora Biosciences, 2022

Familial Adenomatous Polyposis – Pipeline by FunPep Co Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by Johnson & Johnson, 2022

Familial Adenomatous Polyposis – Pipeline by KD Pharma Group SA, 2022

Familial Adenomatous Polyposis – Pipeline by Recursion Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by SanaRx Biotherapeutics Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Stemsynergy Therapeutics Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by TherapyX Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Thetis Pharmaceuticals LLC, 2022

Familial Adenomatous Polyposis – Dormant Projects, 2022

Familial Adenomatous Polyposis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Familial Adenomatous Polyposis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.